Biotech Values

[Titan V]

SRPT opens up about Duchenne drug launch, allays investors' worst fears
https://www.thestreet.com/story/13948568/1/sarepta-opens-up-about-duchenne-drug-launch-allays-investors-worst-fears.html

Sarepta Therapeutics (SRPT) is providing two numbers Tuesday that should wipe away the worst fears investors have had about the commercial launch of Exondys 51, its newly approved treatment for boys with Duchenne muscular dystrophy (DMD.).

In the fourth quarter, Sarepta recorded $5.4 million in sales of Exondys 51, the company said. The drug was approved on Sept. 19.

Street expectations for Exondys 51 sales in its first quarter of commercial launch have been volatile and widely divergent but the analyst consensus was $4.9 million, according to Factset.